SFE Investment Counsel Has $2.95 Million Stock Position in Pfizer Inc. $PFE

SFE Investment Counsel grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 33.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 122,530 shares of the biopharmaceutical company’s stock after acquiring an additional 30,975 shares during the period. SFE Investment Counsel’s holdings in Pfizer were worth $2,951,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the fourth quarter valued at $26,000. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $26,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the last quarter. Evolution Wealth Management Inc. lifted its stake in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the period. Finally, Abound Financial LLC bought a new stake in Pfizer in the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on PFE shares. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. JPMorgan Chase & Co. dropped their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. Finally, BMO Capital Markets dropped their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.28.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 melanoma results for their personalized mRNA cancer-vaccine combination with Keytruda, demonstrating improved recurrence-free survival. Pfizer is not directly involved, but the data lifted sentiment across mRNA and oncology companies and highlighted the potential value of Pfizer’s own cancer-vaccine ambitions. Pfizer Stock Rises Wednesday: What’s Going On?
• Positive Sentiment: Pfizer and Valneva received validation from the European Medicines Agency for their Lyme disease vaccine application, allowing the filing to proceed to full regulatory review after encouraging late-stage efficacy and safety results. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Unusually heavy call-option activity indicated increased speculative interest: investors bought 170,284 call options, roughly 47% above typical daily volume. This is a sentiment signal rather than a change to Pfizer’s fundamentals.
• Positive Sentiment: Pfizer’s potential monthly obesity treatment, berobenatide, could provide entry into the fast-growing GLP-1 market if clinical development and market-share objectives are achieved. Pfizer’s Obesity Push
• Neutral Sentiment: Merck’s increased investment in personalized cancer vaccines raises the competitive bar for Pfizer and BioNTech. The development validates the market opportunity but could make it harder for Pfizer to differentiate its pipeline. Merck Just Raised the Stakes for Pfizer’s Cancer Vaccine Ambitions
• Negative Sentiment: Investors continue to debate Pfizer’s looming patent cliff, which could pressure revenue as key products face loss-of-exclusivity risk. The stock’s relatively low valuation and dividend appeal may partly reflect these concerns. Pfizer: Still Cheap Valuation Meets a Looming Patent Cliff

Pfizer Stock Performance

Shares of PFE stock opened at $28.25 on Thursday. The firm has a 50 day moving average of $25.23 and a 200-day moving average of $26.23. The company has a market cap of $161.00 billion, a price-to-earnings ratio of 37.17 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. Pfizer’s dividend payout ratio is currently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.